Purpose

Tangzhiqing formula (TZQ) is a traditional Chinese medicine prescribed to treat lipid metabolism disorders, atherosclerosis, diabetes and diabetic cardiomyopathy. However, some challenges and hurdles remain. TZQ showed promising results in treating diabetes and hyperlipidaemia. However, its effect on and mechanism of action in hyperlipidaemia complicated with myocardial ischaemia (HL-MI) remain unknown.

Methods

In this study, a network pharmacology-based strategy integrating target prediction was adopted to predict the targets of TZQ relevant to the treatment of HL-MI and to further explore the involved pharmacological mechanisms.

Results

A total of 104 potential therapeutic targets were obtained, including MMP9, Bcl-2, and Bax, which may be related to the apoptosis and PI3K/AKT signalling pathways. Then, we confirmed these potential targets and pathways with animal experimentation. TZQ reduced lipid levels, increased the expression levels of Bcl-2, decreased Bax, caspase-3 and caspase-9 expression levels, and activated the PI3K/AKT signalling pathway.

Conclusion

In conclusion, this study provides new insights into the protective mechanisms of TZQ against HL-MI through network pharmacology and pharmacological approaches.

中文翻译：

---

糖脂清改善高脂血症并发心肌缺血小鼠心功能的作用及机制

目的

糖脂清方 (TZQ) 是一种用于治疗脂质代谢紊乱、动脉粥样硬化、糖尿病和糖尿病性心肌病的中药。然而，一些挑战和障碍仍然存在。TZQ 在治疗糖尿病和高脂血症方面显示出可喜的结果。然而，其对高脂血症并发心肌缺血（HL-MI）的影响及作用机制尚不清楚。

方法

在本研究中，采用基于网络药理学的靶点预测策略来预测 TZQ 治疗 HL-MI 的相关靶点，并进一步探索相关的药理机制。

结果

共获得104个潜在治疗靶点，包括MMP9、Bcl-2、Bax，可能与细胞凋亡和PI3K/AKT信号通路有关。然后，我们通过动物实验证实了这些潜在的目标和途径。TZQ 降低脂质水平，增加 Bcl-2 的表达水平，降低 Bax、caspase-3 和 caspase-9 的表达水平，并激活 PI3K/AKT 信号通路。

结论

总之，本研究通过网络药理学和药理学方法为 TZQ 对 HL-MI 的保护机制提供了新的见解。